Moderna’s stock soars on ‘compelling’ early data for its coronavirus vaccine candidate

The people who were given Moderna Inc.’s (TICKER:MRNA) coronavirus vaccine candidate in a Phase 1 clinical trial developed neutralizing antibodies, a promising finding that has propelled the vaccine into the next phase of clinical testing.